A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Life expectancy at least 12 weeks

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Adequate hematologic and end-organ function

• Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1

• Histologically confirmed locally advanced, recurrent, or metastatic incurable solidtumor malignancy

• Availability of representative tumor specimens required for patients in selectcohorts.

Exclusion Criteria:

• Women who are pregnant or breastfeeding

• Any anti-cancer therapy, whether investigational or approved, includingchemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior toinitiation of study treatment

• Active hepatitis B or C or tuberculosis

• Positive test for human immunodeficiency virus (HIV) infection

• Acute or chronic active Epstein-Barr virus (EBV) infection at screening

• Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks beforefirst RO7759065 infusion

• Primary, untreated, or active central nervous system (CNS) metastases

• Active or history of autoimmune disease or immune deficiency

• Prior allogeneic stem cell or organ transplantation

• Any history of a Grade 3 immune-mediated adverse event attributed to prior cancerimmunotherapy that resulted in permanent discontinuation of that agent

• Any history of a Grade 4 immune-mediated adverse event attributed to prior cancerimmunotherapy.